# A Study To Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects

> **NCT06576401** · PHASE1 · RECRUITING · sponsor: **Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.** · enrollment: 10 (estimated)

## Conditions studied

- Healthy Adult Subject

## Interventions

- **DRUG:** [14C] HDM1002

## Key facts

- **NCT ID:** NCT06576401
- **Lead sponsor:** Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-27
- **Primary completion:** 2024-10
- **Final completion:** 2024-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06576401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06576401, "A Study To Characterize Mass Balance Of [14C] HDM1002 in Chinese Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06576401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*